OLIGOPELVIS - GETUG P07: a multicentre phase II trial of combined salvage radiotherapy and hormone therapy in oligometastatic pelvic node relapses of prostate cancer.

Metastatic prostate cancer remains a common cause of death in Europe, and improvements in management of the disease are urgently needed. The advent of positron-emission tomography (PET) imaging enhanced with fluorocholine has led to the identification of a new sub-group of metastatic prostate cancer patients: those with so-called oligometastatic disease.

Presenting with a low burden of metastatic disease (≤5 lesions), this new sub-group lies between true metastatic prostate cancer patients for whom androgen- deprivation therapy (ADT) is the mainstay of treatment, and patients with a rising PSA, but no visible lesion on conventional imaging, in whom intermittent ADT has been shown to be no less effective than continuous ADT. One might conclude that intermittent ADT would also be the standard of care for oligometastatic prostate cancer patients, but radical strategies such as extensive lymphadenectomy or high-dose radiotherapy have been suggested as another means to delay the need for ADT, and increase its effectiveness once initiated. This study will explore the role of salvage pelvic image-guided intensity-modulated radiation therapy (IMRT) combined with ADT administered for 6 months in pelvic oligometastatic patients in prolonging the failure-free interval between two consecutive ADT courses, or even to cure selected patients with limited metastatic burden.

We plan to assess the two year outcome in oligometastatic prostate cancer patients (1-5 pelvic oligometastases) treated concomitantly with high-dose IMRT (54 Gy, 30 fractions to the pelvis and 66 Gy, 30 fractions to the lymph nodes) and ADT for six months.

This multicenter prospective phase II study will yield new data regarding the safety and efficacy of high-dose radiotherapy combined with ADT and will provide a basis for a larger phase III study to examine the role of radiotherapy in this population currently treated only with hormone therapy.

NCT02274779 , date of registration: 23/10/14.

BMC cancer. 2015 Sep 25*** epublish ***

Stephane Supiot, Emmanuel Rio, Valérie Pacteau, Marie-Hélène Mauboussin, Loïc Campion, François Pein

Department of Radiation Oncology, Institut de Cancérologie de l'Ouest, Boulevard J. Monod, F-44800, Nantes, St-Herblain, France. stephane. supiot@ico. unicancer. fr. , Department of Radiation Oncology, Institut de Cancérologie de l'Ouest, Boulevard J. Monod, F-44800, Nantes, St-Herblain, France. emmanuel. rio@ico. unicancer. fr. , Department of Research, Institut de Cancérologie de l'Ouest-René Gauducheau, boulevard Jacques Monod, Saint Herblain, 44800, France. valerite. pacteau@ico. unicancer. fr. , Department of Research, Institut de Cancérologie de l'Ouest-René Gauducheau, boulevard Jacques Monod, Saint Herblain, 44800, France. marie-helene. mauboussin@ico. unicancer. fr. , Centre de Recherche en Cancérologie Nantes-Angers (CRCNA), UMR 892 Inserm - 6299 CNRS, Institut de Recherche en Santé de l'Université de Nantes, 8 quai Moncousu, BP 70721, 44007, Nantes cedex 1, France. loic. campion@ico. unicancer. fr. , Department of Research, Institut de Cancérologie de l'Ouest-René Gauducheau, boulevard Jacques Monod, Saint Herblain, 44800, France.  

PubMed

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe